Research Summary

I am an imaging scientist and breast cancer researcher with broad experience in the area of biomedical research. Work in my laboratory focuses on the development of MRI techniques for breast cancer diagnosis and treatment response assessment. My laboratory works closely with a multi-disciplinary team of radiologists, surgeons, oncologists, basic science researchers and advocates to optimize MRI methods for the clinical management of breast cancer patients. The overall goal of our interdisciplinary research program is to develop imaging-based biomarkers that can be used in combination with clinical and molecular information to individualize treatment strategies.

I lead as Principal Investigator, the multi-center ACRIN trials 6657 and 6698, evaluating dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI respectively, for assessing treatment response as part of the ISPY-1 and ISPY-2 neoadjuvant breast cancer trials. Under an NCI Academic-Industrial Partnership (AIP) grant with commercial partner Hologic, Inc., (R01 CA132870), my laboratory developed and deployed a software platform for real-time measurement of breast tumor response using DCE-MRI, for use in clinical trials. The Hologic software received FDA IDE approval in 2010 and is now incorporated in the response-adaptive patient randomization engine of ISPY-2. Under prior funding from the NCI Quantitative Imaging Network (QIN) (U01 CA151235), my laboratory led efforts to improve the integration of quantitative imaging (QI) in breast cancer clinical trials through the development of standards and quality control processes and improved diffusion-weighted MRI approaches for tumor response measurement.

As an applied scientist involved in the early development of breast MRI, I believe I bring a unique perspective and appreciation of the factors that drive and shape the development of new breast imaging technologies. I have served on and chaired numerous grant review panels in both the areas of medical imaging and breast cancer research.

I am an active educator and faculty member at UCSF and in the UCSF/UC Berkeley Bioengineering Graduate Program and I teach formally in the UCSF Master’s in Biomedical Imaging degree program. I have been involved in the training and research supervision of graduate students, post-doctoral fellows and junior faculty for over 20 years.

Research Funding

  • April 25, 2008 - June 30, 2020 - Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA132870
  • September 26, 2011 - August 31, 2016 - Quantitative Imaging for Assessing Breast Cancer Response to Treatment, Principal Investigator. Sponsor: NIH, Sponsor Award ID: U01CA151235
  • August 23, 2006 - July 31, 2013 - MRI For Staging DCIS and Assessing Response to Treatment, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01CA116182
  • June 1, 1993 - May 31, 2013 - NMR Imaging and Spectroscopy, Co-Investigator. Sponsor: NIH, Sponsor Award ID: P41RR008079

Education

Massachusetts Institute of Technology (M.I.T.), B.S., 1979, Chemical Engineering
Stanford University, Ph.D., 1985, Applied Physics

Honors & Awards

  • 2010
    Komen Scholar, Komen for the Cure
  • 2013
    Distinguished Lectureship Award, Sigma Xi
  • 2013
    Distinguished Investigator Award, Academy of Radiology Research
  • 2017
    Fellow, International Society of Magnetic Resonance in Medicine

Selected Publications

  1. Whisenant JG, Romanoff J, Rahbar H, Kitsch AE, Harvey SM, Moy L, DeMartini WB, Dogan BE, Yang WT, Wang LC, Joe BN, Wilmes LJ, Hylton NM, Oh KY, Tudorica LA, Neal CH, Malyarenko DI, McDonald ES, Comstock CE, Yankeelov TE, Chenevert TL, Partridge SC Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702).  View on PubMed
  2. Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.  View on PubMed
  3. Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.  View on PubMed
  4. McDonald ES, Romanoff J, Rahbar H, Kitsch AE, Harvey SM, Whisenant JG, Yankeelov TE, Moy L, DeMartini WB, Dogan BE, Yang WT, Wang LC, Joe BN, Wilmes LJ, Hylton NM, Oh KY, Tudorica LA, Neal CH, Malyarenko DI, Comstock CE, Schnall MD, Chenevert TL, Partridge SC Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial.  View on PubMed
  5. Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.  View on PubMed
  6. Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.  View on PubMed
  7. Tan ET, Wilmes LJ, Joe BN, Onishi N, Arasu VA, Hylton NM, Marinelli L, Newitt DC Denoising and Multiple Tissue Compartment Visualization of Multi-b-Valued Breast Diffusion MRI.  View on PubMed
  8. Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.  View on PubMed
  9. Nguyen AA, Arasu VA, Strand F, Li W, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LJ, Newitt DC, Hylton NM Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.  View on PubMed
  10. Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.  View on PubMed
  11. Newitt DC, Amouzandeh G, Partridge SC, Marques HS, Herman BA, Ross BD, Hylton NM, Chenevert TL, Malyarenko DI Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial.  View on PubMed
  12. Malyarenko DI, Newitt DC, Amouzandeh G, Wilmes LJ, Tan ET, Marinelli L, Devaraj A, Peeters JM, Giri S, Vom Endt A, Hylton NM, Partridge SC, Chenevert TL Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study.  View on PubMed
  13. Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.  View on PubMed
  14. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.  View on PubMed
  15. Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).  View on PubMed
  16. Houghton LC, Jung S, Troisi R, LeBlanc ES, Snetselaar LG, Hylton NM, Klifa C, Van Horn L, Paris K, Shepherd JA, Hoover RN, Dorgan JF Pubertal timing and breast density in young women: a prospective cohort study.  View on PubMed
  17. Jahani N, Cohen E, Hsieh MK, Weinstein SP, Pantalone L, Hylton N, Newitt D, Davatzikos C, Kontos D Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration.  View on PubMed
  18. Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, Esserman LJ, Hylton NM Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.  View on PubMed
  19. Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.  View on PubMed
  20. Partridge SC, Newitt DC, Chenevert TL, Rosen MA, Hylton NM Diffusion-weighted MRI in Multicenter Trials of Breast Cancer.  View on PubMed

Go to UCSF Profiles, powered by CTSI